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Edited by Michael R. SussmanAbstract The cells responsible for bone formation express pro-
tease-activated receptors. Although serine protease thrombin has
been shown to elicit functional responses in bone cells that impact
on cell survival and alkaline phosphatase activity, nothing is
known about tissue factor, factor VIIa, and factor Xa, the serine
proteases that act upstream of thrombin in the coagulation cas-
cade. This paper demonstrates that tissue factor is expressed in
the osteoblast-like cell line SaOS-2 and, that tissue factor in a
factor VIIa-bound complex induces a transient intracellular
Ca2+ increase through protease-activated receptor-2. In SaOS-
2 cells, factor Xa induced a sustained intracellular Ca2+ re-
sponse, as does SLIGRL, a PAR2-activating peptide, and
PAR-1-dependent cell viability.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Tissue factor (TF) is an integral membrane glycoprotein that
forms a complex with factor VIIa (FVIIa) and leads to factor
X activation (FXa), which subsequently results in the cleavage
of prothrombin into thrombin. Thrombin digests ﬁbrinogen
into ﬁbrin monomers [1]. TF is expressed in non-circulating
and circulating cells [2], as well as organs [3]. Recently, an
alternatively spliced tissue factor (asTF), consisting only of
the extracellular sequence, was identiﬁed in humans and mice
[4].
FVIIa, when bound to TF, activates cells through protease-
activated receptor-2 (PAR-2), whereas FXa can activate cells
through both PAR-2 and PAR-1. The four known PARs be-
long to the G protein-coupled receptor family. PARs activa-
tion results in N-terminus cleavage, which unmasks a new
tethered ligand that then binds intramolecularly to the recep-
tor. Thrombin activates PAR-1, 3, and 4, while trypsin acti-
vates PAR-2 [5]. PAR-1 activation is responsible for various
functional responses, such as platelet aggregation, cell prolifer-
ation, inﬂammation, and angiogenesis. PAR-2 modulates
inﬂammation and angiogenesis [2].
SaOS-2, an established human osteosarcoma cell line, dis-
plays osteoblastic properties, such as alkaline phosphatase
activity, mineralized matrix formation [6], and calcium signal-*Corresponding author. Fax: +32 2 555 6285.
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doi:10.1016/j.febslet.2007.04.078ing [7]. PAR-1 and PAR-2 are both expressed in SaOS-2 [8,9],
as well as in thrombin-mediated responses [8,10]. However
nothing is known about the eﬀects of serine proteases TF–
FVIIa and FXa in osteoblastic-like cells.
This paper shows that SaOS-2 express TF and asTF, and
that FVIIa can induce calcium signaling through PAR-2. Fur-
thermore, we demonstrate that FXa can induce a sustained
calcium signal, mainly through PAR-2 but also through
PAR-1, which results in enhanced cell viability. Finally, in
the presence of TF and FVIIa, FXa can induce stronger
Ca2+ signaling that has a similar pattern to that induced by
free FXa alone, but only through PAR-2.2. Materials and methods
2.1. Materials
TRAP-6 and SLIGRL (Bachem, Bubendorf, Switzerland), DEGR
(Calbiochem Leuven, Belgium), fura-2 AM (Molecular Probes, Mere-
lbeke, Belgium), PCR primers (Eurogentec, Lie`ge, Belgium), factor
VIIa (Novo Nordisk, Bagsvaerd, Denmark), factor Xa (American
Diagnostica, Stamford, CT, USA) were used.
Human soluble tissue factor (sTF) was generously donated by Heno-
gen (Gosselies, Belgium).
2.2. Cell culture
SaOS-2 from ATCC (# HTB-85) were grown in McCoy’s 5A med-
ium, supplemented with 15% heat-inactivated FBS. The human glio-
blastoma cell line U87 was a generous gift of Screcko Gajovic
(University of Zagreb, Croatia); the cell line was grown in Dulbecco’s
Modiﬁed-Eagle Medium supplemented with 10% heat-inactivated FBS
and 2% penicillin/streptomycin. HUVEC were isolated fresh from
umbilical cords using collagenase type II treatment and grown in endo-
thelial cell growth medium in 1% gelatin-coated ﬂasks.
2.3. Immunohistochemistry
SaOS-2 and U87 cells (104 cells/ml) were cultured (2 days, 37 C, 5%
CO2) on coverslips, washed with Tris-buﬀered saline buﬀer 50 mM (pH
7.3), and ﬁxed in 4% paraformaldehyde (pH 7.4). Permeabilization was
achieved using Triton 0.2%, endogenous peroxidases were blocked (3%
H2O2 in methanol), and secondary antibody non-speciﬁc binding was
inhibited using 10% sheep serum. Immunoaﬃnity puriﬁed apoprotein
of human TF antibody (10 lg/ml) (American Diagnostica) was incu-
bated overnight, followed by biotinylated anti-goat IgG incubation.
Staining included avidin–biotin–peroxidase and diaminobenzidine,
with hematoxylin counterstaining.
2.4. Reverse transcriptase (RT)-polymerase chain reaction (PCR)
Cells were grown to conﬂuence, detached, centrifuged and resus-
pended in Tripure Isolation Reagent (Roche, Brussels, Belgium) for
RNA extraction in RNAse free medium. RNA was treated with
RNAse inhibitor and DNAse, then phenol/chloroform puriﬁed. The
resulting RNA was resuspended in water and quantiﬁed using optical
density at 260 nm.blished by Elsevier B.V. All rights reserved.
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RNA heated for 10 min at 70 C with 10 lg/ll Oligo dT, and a mix
of 1 · First-Strand Buﬀer, 25 lM DTT, 1.2 mM dNTPmix, 2 U/ll
RNase inhibitor with 25 U/ll Superscript II reverse transcriptase was
added and heated (42 C, 50 min).
For PCR, 2 ll of cDNA was mixed with 1· PCR buﬀer, 3 mM
MgCl2, 0.4 mM dNTP, 0.05 U/ll Taq polymerase using 5 0-
AGGATGTGAAGCAGACGTACTT-3 0 and 5 0-GATGATGACCA-
CAAATACCACA-3 0 as primers. Forty cycles (heating: 95 C, 1 min;
annealing: 60 C, 1 min; elongation: 72 C, 1.5 min) were used, and
PCR products were resolved in a 1.5% (w/v) agarose gel.
2.5. Calcium signaling
SaOS-2 grown on coverslips were washed with phosphate-buﬀered
saline buﬀer (pH 7.4) and HEPES buﬀer (150 mM NaCl, 6 mM KCl,
4 mM NaHCO3, 1 mM MgCl2, 10 mM HEPES, 5 mM glucose,
0.25% (w/v) bovine serum albumin and 1 mM CaCl2). Cells were
loaded with 2 lM fura-2-AM for 25 min at 37 C. Fura-2 de-esteriﬁca-
tion was achieved after 15 min incubation. Coverslips were mounted in
a 1 ml temperature-controlled (37 C), open chamber placed on an
Olympus IX51 inverted microscope. Agonists diluted in 100 ll were
added to the chamber. Fura-2 ﬂuorescence changes were measured
in individual cells by ratio ﬂuorometry using a camera-based TillVision
imaging system (Till Photonics, Gra¨felﬁng, Germany). Fluorescence
produced by excitation at 340 nm and 380 nm was detected at 510 nm.
2.6. Cell viability
The cells were washed with phosphate-buﬀered saline (pH 7.4) and
incubated for 3 h with 0.1% (v/v) 3-[4,5-dimethhylthiazol-2-yl]-2,5-
duphenyl-tetrazolium bromide (MTT) in RPMI 1640 medium. After
centrifugation (400 · g, 5 min), the medium was replaced by dimethyl-
sulfoxide (DMSO). Relative cell viability was measured by colorimetry
(570 nm) using a 96-well plate MRX reader (Dynex Technologies,
Chantilly, VA, USA).
2.7. Statistics
The data are shown as means ± S.E.M. Statistical signiﬁcance was
determined using ANOVA and the Bonferroni post hoc analysis avail-
able in Prism 4 software (Graph Pad Inc.).Fig. 1. TF expression on the osteoblast-like cell line SaOS-2. (A) TF immun
cell types (left). TF immunohistochemistry using anti-TF antibody saturated
(B) mRNA expression of TF and asTF. Lane 1: MW; lane 2: SaOS-2 cDNA
cDNA (12 lg), lane 6: no cDNA; lanes 7, 8, 9: SaOS-2, U87, HUVEC cDN3. Results
3.1. SaOS-2 express tissue factor and alternatively spliced tissue
factor
Tissue factor expression was assessed by immunohistochem-
istry and RT-PCR. U87 (positive control [11]) and SaOS-2 were
TF immunoreactive (Fig. 1A, left panel). The speciﬁcity of the
immunoreactivity was controlled using either anti-TF antibody
pre-incubated overnight with sTF (600 lg/ml) or in the absence
of anti-TF antibody. (Fig. 1A, central and right panels).
The TF PCR showed an ampliﬁed cDNA band of expected
length (505 bp) in SaOS-2 and in U87 (Fig. 1B, lanes 2 and 4).
In our system, stimulated HUVECs also expressed TF
(Fig. 1B, lane 5). In SaOS-2 and U87, an additional 355 bp
cDNA band was seen, which probably corresponds to asTF,
which was lacking in HUVEC [12]. No ampliﬁed cDNA band
was detected when the PCR was performed without cDNA or
primers (Fig. 1B, lanes 6–9).
3.2. Factor VIIa induced a low, transient [Ca2+]i response in
SaOS-2
Since FVIIa interacts with TF to form the TF–FVIIa com-
plex, we examined whether the addition of FVIIa could initiate
a calcium response in SaOS-2.
FVIIa (50 nM) triggered a transient [Ca2+]i increase
(Fig. 2A) with a modest intensity in some of the cell popula-
tions (Table 1). Stimulation with SLIGRL, which is a PAR-2
agonist, was inhibited by more than 65% after FVIIa
stimulation, whereas FVIIa pre-stimulation did not aﬀect the
calcium response induced by TRAP-6, a PAR-1 speciﬁc
agonist (Table 2).
A comparison of the [Ca2+]i responses induced by either
FVIIa (generating TF–FVIIa) or FVIIa initially coupled toohistochemistry of U87 and SaOS-2 revealed positive staining in both
by sTF (center) or without anti-TF antibody (right); scale bar = 10 lm.
(10.7 lg); lane 3 empty; lane 4: U87 cDNA (8.7 lg); lane 5: HUVEC
A, respectively, without primers.
Fig. 2. SaOS-2 cells calcium response to FVIIa, sTF–FVIIa, or FXa, with or without TF–FVIIa. Representative traces of [Ca2+]i changes in SaOS-2
stimulated with (A, thin line) FVIIa (50 nM), (A, thick line) sTF–FVIIa (50 nM) or (A, dashed line) solvent DMSO; with (B, thick line) FXa
(50 nM), (B, thin line) SLIGRL (10 lM) or (B, dashed line) solvent DMSO; with (C, ﬁrst arrow) FXa (50 nM) followed (C, second arrow) by DEGR
addition (1lM). Arrows indicate time of addition. (D) [Ca2+]i increase induced by FXa (50 nM), with or without FVIIa (50 nM) or sTF–FVIIa
(50 nM). Data are percentages of FXa-induced [Ca2+]i increase (average of minimum 20 cells from three independent experiments). (E) Fraction of
SaOS-2 responding to FVIIa (50 nM), sTF–FVIIa (50 nM), FXa (50 nM) with or without FVIIa (50 nM) or sTF–FVIIa (50 nM) (average of
minimum 20 cells from three independent experiments; statistical comparisons refer to columns 4 and 5).
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tion, pre-stimulation with sTF–FVIIa aﬀected the SLIGRL-in-
duced calcium response by 45%, but did not aﬀect the TRAP-
6-induced calcium response (Table 2); this demonstrates that
sTF–FVIIa also acts through PAR-2.3.3. Factor Xa induces a sustained calcium signal in SaOS-2
In the coagulation cascade, TF–FVIIa complex activates
FXa. Therefore, we examined whether FXa could also activate
SaOS-2 through intracellular calcium signaling.
FXa induced a Ca2+ response (Table 1) with a typical pat-
tern consisting of oscillations, in addition to inducing a sus-
tained increase in calcium (Fig. 2B). The eﬀect was noted in
66.36 ± 3.7% of SaOS-2.Table 1
[Ca2+]i increase and percentage of responding SaOS-2 cells stimulated wit
(average of 15 cells minimum from three independent experiments)
FVIIa (50 nM) STF–FVIIa (50 nM) FX
10
D[Ca2+]i (nM) 37.4 ± 4.3 47.4 ± 8.4 27
Responding cells (%) 52.6 ± 7.5 49.90 ± 10.9 75FXa has been shown to stimulate both PAR-1 and PAR-2
receptors. In SaOS-2, FXa pre-stimulation signiﬁcantly de-
creased the cells’ responses to SLIGRL (85%) and TRAP-6
(30%) (Table 2); this indicates that, in SaOS-2, PAR-2 is the
main mediator of FXa-induced calcium increase. In addition,
SLIGRL (Fig. 2B) or trypsin (data not shown) induced a sig-
nal shape similar to FXa, which further supports PAR-2 as the
main receptor for FXa.
An active FXa site is required for a calcium response to oc-
cur, since pre-incubation with DEGR, an FXa active site
inhibitor, did not induce any detectable [Ca2+]i increase (data
not shown). In addition, adding DEGR during FXa signaling
initiated a rapid decrease of the [Ca2+]i signal (Fig. 2C); this
suggests that the sustained phase pattern of the [Ca2+]i signal-
ing is dependent on the presence of an active FXa site.h FVIIa, sTF–FVIIa, FXa increasing concentrations, and SLIGRL
a SLIGRL (1 lM)
nM 50 nM 100 nM
.10 ± 3.4 74.92 ± 4.1 103.00 ± 8.1 133.30 ± 9.3
.80 ± 7.3 68.52 ± 4.6 61.02 ± 21.2 71.35 ± 15.2
Table 2
Calcium increase in SaOS-2 cells stimulated with either TRAP-6 or SLIGRL without pre-stimulation or pre-stimulated 120 s with either FVIIa, sTF–
FVIIa or FXa
Pre-incubation
FVIIa(50 nM) STF–FVIIa (50 nM) FXa (50 nM)
TRAP-6 (1 lM) 85.42 nM ± 2.9 nM 88.65 nM ± 5.4 nM 82.82 nM ± 8.3 nM 61.61 nM ± 8.6 nM *
SLIGRL (1 lM) 133.30 nM ± 9.3 nM 45.75 nM ± 4.9 nM *** 73.23 nM ± 10.1 nM ** 19.34 nM ± 2.1 nM ***
*P < 0.05.
**P < 0.01.
***P < 0.001 (average of 15 cells minimum from three independent experiments; statistical comparisons are with column 1).
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signal
In vivo, factor X zymogen binds to the TF–FVIIa complex.
Although TF–FVIIa–FXa is a transient complex, in vivo FXa
must act in the presence of TF–FVIIa. Using SaOS-2, FXa-in-
duced calcium signaling was assessed in the presence of TF–
FVIIa, and was compared to calcium signaling with TF–
FVIIa, sTF–FVIIa, or FXa stimulation.
After FXa stimulation with TF–FVIIa or sTF–FVIIa, a
higher [Ca2+]i signal amplitude was reached than with prote-
ases alone (Fig. 2D). The curve shape was similar to that pro-
duced by FXa alone (data not shown), and, in this case, 100%
of the cells were triggered (Fig. 2E).
3.5. Factor X alone, but not TF–FVIIa, induced SaOS-2 cell
viability
SaOS-2 cell viability, which is one of the known biological
responses of serine protease activation, was studied. FXa,
but not TF–FVIIa or sTF–FVIIa, induced cell viabilityFig. 3. Free FXa induces cell viability (A) SaOS-2 cell viability (36 h incuba
(50 nM) with DEGR (1 lM), FVIIa (50 nM) and sTF–FVIIa (50 nM). (B) S
(50 nM), with or without FVIIa (50 nM) or sTF–FVIIa complex (50 nM).(
TRAP-6 (10 lM) and SLIGRL (10 lM). Proteases and agonists were dilu
medium. Average value of 24 wells from three independent experiments.(Fig. 3A). In the presence of DEGR, FXa-induced cell viability
was abolished (Fig. 3A). Interestingly, when FXa was associ-
ated with TF and FVIIa, its ability to induce cell viability
was lost (Fig. 3B). Furthermore, SaOS-2 stimulation with the
speciﬁc activating peptides for PAR-1 (TRAP-6) and PAR-2
(SLIGRL) revealed that only PAR-1 was involved in cell via-
bility (Fig. 3C).4. Discussion
This study demonstrates that osteoblastic-like cells express
TF, which completes the pool of connective tissue cell types
that express TF. In vivo, the bone marrow cavity is crossed
by blood vessels, which are essential for bone formation and
remodeling to occur. It is possible that osteoblasts, through
TF, act in the bone marrow cavity to stop bleeding, in a man-
ner similar to connective tissue cells. Of course, this presumes
that this osteosarcoma cell line has a phenotype that is similartion) in serum-starved medium, or stimulated with FXa (50 nM), FXa
aOS-2 cell viability in serum-starved medium, or stimulated with FXa
C) SaOS-2 cell viability in serum-starved medium, or stimulated with
ted in serum-starved medium. 100% are from 15% serum-containing
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the present, all of the tumor cell lines that have been studied
have been shown to express TF [13]. Thus, further experiments
dealing with, for example, puriﬁed primary cultured human
osteoblasts, are needed.
Recent developments indicate that TF, when bound to
FVIIa, is involved in cell signaling, especially through PAR-2
activation [2]. In this paper, we showed that, in an osteoblas-
tic-like cell line, TF is expressed and acts as a signaling factor.
Abraham et al. [9] have previously detected PAR-2 expression
in SaOS-2 cells. In the present study, this ﬁnding was extended
by demonstrating that FVIIa induced PAR-2-dependent cal-
cium signaling when bound to TF.
The peculiar calcium response pattern shown after FXa-in-
duced PAR-2 activation deserves some discussion. In osteo-
blastic-like cells, FXa induces a combined pattern of
oscillations and a sustained plateau. This pattern is very much
attenuated when other cell types are exposed to FXa. The cal-
cium response pattern shows either oscillations [14] or a sus-
tained response [15]. One explanation could be that the
PAR-2 density is higher in SaOS-2 cells. Indeed, our prelimin-
ary experiments using quantitative PCR indicated that PAR-2
density was times higher in SaOS-2 cells compared to HU-
VECs (data not shown). Another explanation that acknowl-
edges that PAR-2 density may not be the only parameter
generating diﬀerent calcium response patterns is the ‘‘signalo-
some concept’’ [16]. The signalosome concept takes into ac-
count that each cell type, through diﬀerentiation, develops its
own toolkit of signaling components that can deliver calcium
signals with very diﬀerent spatial and temporal properties.
An important role of the TF–FVIIa complex is illustrated by
the fact that its presence with FXa facilitated a more eﬃcient
response. This role has already been noted in CHO cells [17].
In a similar vein, in the present study, it was found that
FXa, in the presence of TF–FVIIa complex, induced signaling
only through the PAR-2 receptor. This conclusion is supported
by our cell viability experiment, which is a process that de-
pends only on PAR-1 signaling. Thus, this favors the fact that,
in vivo, FXa acts only through PAR-2; PAR-1 is then avail-
able for thrombin-induced activation.
In conclusion, it appears that serine proteases may play an
important role in bone survival and bone reconstruction after
injury.
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